HRP20110478T1 - Modificiranje liječenja pirfenidonom za pacijente s atipičnom funkcijom jetre - Google Patents
Modificiranje liječenja pirfenidonom za pacijente s atipičnom funkcijom jetre Download PDFInfo
- Publication number
- HRP20110478T1 HRP20110478T1 HR20110478T HRP20110478T HRP20110478T1 HR P20110478 T1 HRP20110478 T1 HR P20110478T1 HR 20110478 T HR20110478 T HR 20110478T HR P20110478 T HRP20110478 T HR P20110478T HR P20110478 T1 HRP20110478 T1 HR P20110478T1
- Authority
- HR
- Croatia
- Prior art keywords
- pirfenidone
- patient
- day
- liver function
- administered
- Prior art date
Links
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 title claims abstract 36
- 229960003073 pirfenidone Drugs 0.000 title claims abstract 36
- 230000003908 liver function Effects 0.000 title claims abstract 13
- 239000000090 biomarker Substances 0.000 claims abstract 12
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims abstract 10
- 108010082126 Alanine transaminase Proteins 0.000 claims abstract 10
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims abstract 10
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims abstract 10
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims abstract 8
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims abstract 8
- 230000002159 abnormal effect Effects 0.000 claims abstract 4
- 230000005856 abnormality Effects 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11310708P | 2008-11-10 | 2008-11-10 | |
US12/428,393 US7566729B1 (en) | 2008-11-10 | 2009-04-22 | Modifying pirfenidone treatment for patients with atypical liver function |
US22894309P | 2009-07-27 | 2009-07-27 | |
US12/553,292 US7635707B1 (en) | 2008-11-10 | 2009-09-03 | Pirfenidone treatment for patients with atypical liver function |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20110478T1 true HRP20110478T1 (hr) | 2011-07-31 |
Family
ID=41427890
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110478T HRP20110478T1 (hr) | 2008-11-10 | 2011-06-28 | Modificiranje liječenja pirfenidonom za pacijente s atipičnom funkcijom jetre |
HRP20141224AT HRP20141224T1 (en) | 2008-11-10 | 2014-12-17 | Pirfenidone treatment for patients with atypical liver function |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20141224AT HRP20141224T1 (en) | 2008-11-10 | 2014-12-17 | Pirfenidone treatment for patients with atypical liver function |
Country Status (39)
Country | Link |
---|---|
US (9) | US7635707B1 (de) |
EP (4) | EP2505199A1 (de) |
JP (3) | JP2012508253A (de) |
KR (1) | KR101699501B1 (de) |
CN (1) | CN102209543A (de) |
AP (1) | AP2011005740A0 (de) |
AT (1) | ATE503480T1 (de) |
AU (3) | AU2009313302B2 (de) |
BR (1) | BRPI0921022A2 (de) |
CA (2) | CA2709997C (de) |
CL (1) | CL2011000966A1 (de) |
CO (1) | CO6382132A2 (de) |
CU (1) | CU20110100A7 (de) |
CY (2) | CY1111595T1 (de) |
DE (1) | DE602009000986D1 (de) |
DK (2) | DK2191831T3 (de) |
EA (1) | EA022482B1 (de) |
EC (1) | ECSP11011039A (de) |
ES (3) | ES2387421T3 (de) |
GE (1) | GEP201706719B (de) |
HK (3) | HK1153668A1 (de) |
HR (2) | HRP20110478T1 (de) |
IL (1) | IL212064A (de) |
MA (1) | MA32880B1 (de) |
ME (1) | ME01189B (de) |
MX (1) | MX2011004904A (de) |
MY (1) | MY159353A (de) |
NI (1) | NI201100091A (de) |
PE (1) | PE20110683A1 (de) |
PL (2) | PL2343070T3 (de) |
PT (2) | PT2343070E (de) |
RS (2) | RS51787B (de) |
SI (2) | SI2343070T1 (de) |
SM (2) | SMT201100030B (de) |
SV (1) | SV2011003897A (de) |
TN (1) | TN2011000217A1 (de) |
TW (2) | TW201341361A (de) |
WO (1) | WO2010054294A1 (de) |
ZA (1) | ZA201102411B (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5627574B2 (ja) | 2008-06-03 | 2014-11-19 | インターミューン, インコーポレイテッド | 炎症性および線維性疾患を治療するための化合物および方法 |
US7635707B1 (en) | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
US20100190731A1 (en) * | 2009-01-26 | 2010-07-29 | Jeff Olgin | Methods for treating acute myocardial infarctions and associated disorders |
US7816383B1 (en) | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
DK2670242T3 (da) | 2011-01-31 | 2022-05-02 | Avalyn Pharma Inc | Aerosolpirfenidon- og pyridonanalogforbindelser og anvendelser deraf |
JP5259026B1 (ja) * | 2011-10-13 | 2013-08-07 | 三井化学株式会社 | 高分子圧電材料、およびその製造方法 |
JP2015506944A (ja) * | 2012-01-18 | 2015-03-05 | ジェネンテック, インコーポレイテッド | Fgf19修飾薬を使用する方法 |
MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
CA2819967C (en) * | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
US9682071B2 (en) | 2013-03-15 | 2017-06-20 | Intermune, Inc. | Methods of improving microvascular integrity |
EP3091976A4 (de) | 2014-01-10 | 2017-10-11 | Genoa Pharmaceuticals Inc. | Aerosolförmige pirfenidon- und pyridonanalogverbindungen und verwendungen davon |
CA2936245A1 (en) * | 2014-01-24 | 2015-07-30 | Auspex Pharmaceuticals, Inc. | Substituted n-aryl pyridinones |
DK3122349T3 (da) * | 2014-03-25 | 2022-02-14 | Leading Biosciences Inc | Sammensætninger til behandling af autodigestion |
CA2943363A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
WO2016127013A1 (en) * | 2015-02-05 | 2016-08-11 | Memorial Sloan Kettering Cancer Center | Compositions and methods for treatment of edema |
MA41544A (fr) * | 2015-02-19 | 2017-12-26 | Novartis Ag | Dosages de panobinostat pour le traitement du myélome multiple |
CN108289883A (zh) * | 2015-12-11 | 2018-07-17 | 豪夫迈·罗氏有限公司 | 维莫德吉与吡非尼酮联合疗法 |
CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
WO2018026442A1 (en) * | 2016-08-01 | 2018-02-08 | The Regents Of The University Of California | Small molecule inhibition for preventing or treating fibrotic diseases |
MX364040B (es) * | 2016-11-11 | 2019-04-11 | Cell Therapy And Tech S A De C V | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
EP3664847A1 (de) * | 2017-08-12 | 2020-06-17 | AiViva Biopharma, Inc. | Multikinase-hemmer und verwendungen bei fibrose des fortpflanzungs- und verdauungstraktes |
MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
EP3836927A4 (de) * | 2018-08-15 | 2022-05-11 | AiViva Biopharma, Inc. | Multikinase-inhibitoren von vegf und tgf-beta und deren verwendungen |
WO2021057599A1 (zh) * | 2019-09-26 | 2021-04-01 | 深圳先进技术研究院 | 吡非尼酮在制备防治类风湿性关节炎的药物中的应用 |
CA3160410A1 (en) | 2019-12-04 | 2021-06-10 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
WO2023161668A1 (en) | 2022-02-28 | 2023-08-31 | Nuformix Technologies Limited | Compositions and methods for treatment of idiopathic pulmonary fibrosis |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1000828A (en) | 1907-07-25 | 1911-08-15 | Pierre Lorillard | Conveyer. |
US4042699A (en) | 1972-12-18 | 1977-08-16 | Affiliated Medical Research, Inc. | Method for reducing serum glucose levels |
US4052509A (en) | 1972-12-18 | 1977-10-04 | Affiliated Medical Research, Inc. | Method for reducing serum uric acid levels |
CA1049411A (en) | 1972-12-18 | 1979-02-27 | Affiliated Medical Research | N-substituted pyridone and general method for preparing pyridones |
CA1244894A (en) | 1985-09-27 | 1988-11-15 | William A. Cole | Low voltage class b amplifier with low value decoupling capacitors |
JPH02215719A (ja) | 1989-02-15 | 1990-08-28 | Yamauchi Akitomo | 線維化病変組織の修復並びに線維化病変の阻止剤 |
US5518729A (en) | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
US5716632A (en) | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
US5310562A (en) | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
US6956044B1 (en) * | 2000-02-21 | 2005-10-18 | Margolin Solomon B | Compositions and methods for treatment of epilepsy |
SE0101762D0 (sv) | 2001-05-18 | 2001-05-18 | Astrazeneca Ab | New use |
PL372928A1 (en) | 2002-04-10 | 2005-08-08 | Applied Research Systems Ars Holding N.V. | Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease |
US20060110358A1 (en) | 2002-08-28 | 2006-05-25 | Hsu Henry H | Combination therapy for treatment of fibrotic disorders |
JP4542743B2 (ja) | 2002-12-26 | 2010-09-15 | Kdl株式会社 | ピリドン誘導体の溶液状医薬組成物 |
US20070072181A1 (en) | 2003-02-28 | 2007-03-29 | Blatt Lawrence M | Combination therapy for treating alphavirus infection and liver fibrosis |
WO2005011047A2 (en) | 2003-04-09 | 2005-02-03 | Mano Dorsey Judd | Virtual antenna technology (vat) and applications |
CA2525184C (en) | 2003-05-09 | 2012-10-30 | Centocor, Inc. | Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses |
JP2007525188A (ja) | 2003-05-16 | 2007-09-06 | インターミューン インコーポレイテッド | 合成ケモカイン受容体リガンドおよびその使用方法 |
US20070092488A1 (en) | 2003-05-16 | 2007-04-26 | Intermune Inc. | Methods of treating idiopathic pulmonary fibrosis |
US20080025986A1 (en) | 2003-06-06 | 2008-01-31 | Ozes Osman N | Methods of Treating Tnf-Mediated Disorders |
US20070053877A1 (en) | 2003-08-21 | 2007-03-08 | Intermune, Inc. | Methods of treating idiopathic pulmonary fibrosis |
CN1266144C (zh) | 2003-09-01 | 2006-07-26 | 上海凯曼生物科技有限公司 | 黄芩甙和黄芩甙元的用途和剂型 |
WO2005040758A2 (en) * | 2003-10-24 | 2005-05-06 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
CA2544924A1 (en) | 2003-11-05 | 2005-05-19 | Centocor, Inc. | Methods and compositions for treating mcp-1 related pathologies |
CA2545813C (en) | 2003-11-14 | 2011-01-04 | Shanghai Genomics, Inc. | The derivatives of pyridone and use thereof |
WO2005067963A1 (en) | 2003-12-23 | 2005-07-28 | Intermune, Inc. | Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens |
DE10394357T5 (de) * | 2003-12-30 | 2007-03-08 | Council Of Scientific & Industrial Research | Oro-dentale-Kräuterpflegezusammensetzung und Verfahren zur Herstellung derselben |
WO2005091853A2 (en) | 2004-02-27 | 2005-10-06 | Centocor, Inc. | Methods and compositions for treating il-13 related pathologies |
US20070053845A1 (en) | 2004-03-02 | 2007-03-08 | Shiladitya Sengupta | Nanocell drug delivery system |
WO2005110478A2 (en) | 2004-04-13 | 2005-11-24 | Intermune, Inc. | Combination therapy for treating fibrotic disorders |
US20060037057A1 (en) | 2004-05-24 | 2006-02-16 | Sharp Laboratories Of America, Inc. | Method and system of enabling trick play modes using HTTP GET |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
AR051444A1 (es) | 2004-09-24 | 2007-01-17 | Centocor Inc | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos |
US20060246070A1 (en) | 2004-09-30 | 2006-11-02 | Heavner George A | Methods and compositions for treating renal cell carcinoma related pathologies |
JP2008515893A (ja) | 2004-10-05 | 2008-05-15 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 肺線維症を処置するためのtafi阻害剤およびそれらの使用 |
EP1812077A4 (de) | 2004-10-27 | 2009-12-02 | Medimmune Inc | Modulatoren von epha2 und ephrina1 zur behandlung von fibrosebedingten erkrankungen |
WO2006050058A2 (en) | 2004-10-28 | 2006-05-11 | The General Hospital Corporation | Methods of detection and therapy of inflamed tissues using immune modulation |
US20090110633A1 (en) | 2005-03-14 | 2009-04-30 | Shiladitya Sengupta | Nanocells for Diagnosis and Treatment of Diseases and Disorders |
WO2006105538A2 (en) | 2005-03-31 | 2006-10-05 | Centocor, Inc. | Methods and compositions for treating il-21 related pathologies |
CN1846699A (zh) | 2005-04-13 | 2006-10-18 | 中南大学湘雅医院 | 1-(取代苯基)-5-甲基-2-(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用 |
JP2008540345A (ja) | 2005-04-29 | 2008-11-20 | セルジーン・コーポレーション | 1−(5−(1h−1,2,4−トリアゾール−5−イル)(1h−インダゾール−3−イル))−3−(2−ピペリジルエトキシ)ベンゼンの固体形態 |
PT1928454E (pt) | 2005-05-10 | 2014-12-04 | Intermune Inc | Derivativos da piridona para modulação do sistema de proteína quinase ativada pelo stress |
US20090131312A1 (en) | 2005-05-18 | 2009-05-21 | Lawrence Blatt | Non-natural chemokine receptor ligands and methods of use thereof |
RU2007142523A (ru) | 2005-05-18 | 2009-06-27 | БИОГЕН ИДЕК Инк. (US) | Способы лечения фиброзных состояний |
EP2305697A3 (de) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Makrocyclische Inhibitoren der Replikation des Hepatitis-C-Virus |
US20110059069A1 (en) | 2005-09-22 | 2011-03-10 | Biogen Idec Ma Inc | Gapr-1 Methods |
NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
EP1951233B1 (de) | 2005-10-31 | 2012-03-28 | Intermune, Inc. | Zusammensetzungen von pirfenidon/toll-like rezeptor (tlr)-antagonisten und verfahren zu ihrer verwendung zur stimulierung der produktion des granulozyten-kolonie-stimulierenden faktors (g-csf) |
AU2006318428A1 (en) | 2005-11-23 | 2007-05-31 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
US20070203202A1 (en) | 2005-12-02 | 2007-08-30 | Robinson Cynthia Y | Methods of reducing adverse events associated with pirfenidone therapy |
BRPI0709950A2 (pt) | 2006-04-13 | 2011-08-02 | Actelion Pharmaceuticals Ltd | uso de bosentan na preparação de um medicamento para o tratamento de fibrose pulmonar idiopática em estágio precoce e uso de antagonista do receptor endotelin |
US20080003635A1 (en) | 2006-06-12 | 2008-01-03 | Intermune, Inc. | High Throughput Collagen Synthesis Assay |
KR20090024834A (ko) | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 억제제 |
JP5220025B2 (ja) | 2006-12-04 | 2013-06-26 | プロメディオール, インコーポレイテッド | 線維症疾患を処置するための併用療法 |
US7767700B2 (en) * | 2006-12-18 | 2010-08-03 | Intermune, Inc. | Method of providing pirfenidone therapy to a patient |
US20090136512A1 (en) | 2007-03-30 | 2009-05-28 | Peter Bugelski | CXCL13 Antagonists and Their Use for the Treatment of Inflammatory Diseases |
AU2007201663A1 (en) | 2007-04-16 | 2008-10-30 | Nautilus Biotech | Oral dosage formulations of protease resistant polypeptides |
CA2583716A1 (en) | 2007-04-18 | 2008-10-18 | Nautilus Biotech | Oral dosage formulations of protease resistant polypeptides |
US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
US20080287508A1 (en) | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
JP5627574B2 (ja) | 2008-06-03 | 2014-11-19 | インターミューン, インコーポレイテッド | 炎症性および線維性疾患を治療するための化合物および方法 |
US7566729B1 (en) * | 2008-11-10 | 2009-07-28 | Intermune, Inc. | Modifying pirfenidone treatment for patients with atypical liver function |
US7635707B1 (en) | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
-
2009
- 2009-09-03 US US12/553,292 patent/US7635707B1/en active Active
- 2009-11-06 ME MEP-2011-113A patent/ME01189B/de unknown
- 2009-11-06 AT AT09252572T patent/ATE503480T1/de active
- 2009-11-06 EP EP12166073A patent/EP2505199A1/de not_active Withdrawn
- 2009-11-06 ES ES09252572T patent/ES2387421T3/es active Active
- 2009-11-06 PT PT110014149T patent/PT2343070E/pt unknown
- 2009-11-06 EP EP12166074.0A patent/EP2500019B1/de not_active Revoked
- 2009-11-06 EP EP11001414.9A patent/EP2343070B1/de not_active Revoked
- 2009-11-06 ES ES12166074.0T patent/ES2578715T3/es active Active
- 2009-11-06 RS RS20110264A patent/RS51787B/en unknown
- 2009-11-06 PL PL11001414T patent/PL2343070T3/pl unknown
- 2009-11-06 PL PL09252572T patent/PL2191831T3/pl unknown
- 2009-11-06 SI SI200931071T patent/SI2343070T1/sl unknown
- 2009-11-06 SI SI200930033T patent/SI2191831T1/sl unknown
- 2009-11-06 DK DK09252572.4T patent/DK2191831T3/da active
- 2009-11-06 EP EP09252572A patent/EP2191831B1/de active Active
- 2009-11-06 ES ES11001414.9T patent/ES2525543T3/es active Active
- 2009-11-06 DK DK11001414.9T patent/DK2343070T3/en active
- 2009-11-06 RS RS20140692A patent/RS53721B1/en unknown
- 2009-11-06 PT PT09252572T patent/PT2191831E/pt unknown
- 2009-11-06 DE DE602009000986T patent/DE602009000986D1/de active Active
- 2009-11-09 JP JP2011535716A patent/JP2012508253A/ja not_active Withdrawn
- 2009-11-09 PE PE2011000951A patent/PE20110683A1/es not_active Application Discontinuation
- 2009-11-09 TW TW102123162A patent/TW201341361A/zh unknown
- 2009-11-09 BR BRPI0921022A patent/BRPI0921022A2/pt not_active IP Right Cessation
- 2009-11-09 AP AP2011005740A patent/AP2011005740A0/xx unknown
- 2009-11-09 MY MYPI2011002049A patent/MY159353A/en unknown
- 2009-11-09 CA CA2709997A patent/CA2709997C/en active Active
- 2009-11-09 KR KR1020117012538A patent/KR101699501B1/ko active IP Right Grant
- 2009-11-09 EA EA201170669A patent/EA022482B1/ru not_active IP Right Cessation
- 2009-11-09 CN CN2009801444295A patent/CN102209543A/zh active Pending
- 2009-11-09 WO PCT/US2009/063702 patent/WO2010054294A1/en active Application Filing
- 2009-11-09 AU AU2009313302A patent/AU2009313302B2/en not_active Revoked
- 2009-11-09 CA CA2765402A patent/CA2765402A1/en not_active Abandoned
- 2009-11-09 MX MX2011004904A patent/MX2011004904A/es active IP Right Grant
- 2009-11-09 GE GEAP200912257A patent/GEP201706719B/en unknown
- 2009-11-09 US US13/128,569 patent/US8609701B2/en active Active
- 2009-11-09 TW TW098137907A patent/TWI419877B/zh not_active IP Right Cessation
-
2010
- 2010-08-16 AU AU2010212371A patent/AU2010212371B2/en not_active Revoked
- 2010-12-02 HK HK11107951.9A patent/HK1153668A1/xx not_active IP Right Cessation
- 2010-12-02 HK HK10111234.1A patent/HK1145138A1/xx unknown
- 2010-12-02 HK HK13103299.7A patent/HK1176002A1/zh not_active IP Right Cessation
-
2011
- 2011-01-31 AU AU2011200385A patent/AU2011200385B2/en not_active Revoked
- 2011-03-31 ZA ZA2011/02411A patent/ZA201102411B/en unknown
- 2011-03-31 IL IL212064A patent/IL212064A/en active IP Right Grant
- 2011-04-29 CO CO11052726A patent/CO6382132A2/es not_active Application Discontinuation
- 2011-04-29 CL CL2011000966A patent/CL2011000966A1/es unknown
- 2011-05-05 TN TN2011000217A patent/TN2011000217A1/fr unknown
- 2011-05-06 SV SV2011003897A patent/SV2011003897A/es unknown
- 2011-05-06 NI NI201100091A patent/NI201100091A/es unknown
- 2011-05-09 CU CU20110100A patent/CU20110100A7/es unknown
- 2011-05-10 EC EC2011011039A patent/ECSP11011039A/es unknown
- 2011-06-03 MA MA33917A patent/MA32880B1/fr unknown
- 2011-06-28 HR HR20110478T patent/HRP20110478T1/hr unknown
- 2011-06-28 CY CY20111100614T patent/CY1111595T1/el unknown
- 2011-07-15 SM SM201100030T patent/SMT201100030B/it unknown
- 2011-12-06 US US13/312,746 patent/US8592462B2/en active Active
-
2012
- 2012-07-06 JP JP2012152844A patent/JP2012193193A/ja active Pending
-
2013
- 2013-11-12 US US14/078,186 patent/US20140073673A1/en not_active Abandoned
-
2014
- 2014-10-10 JP JP2014208600A patent/JP2015007132A/ja active Pending
- 2014-12-08 CY CY20141101019T patent/CY1115862T1/el unknown
- 2014-12-17 HR HRP20141224AT patent/HRP20141224T1/hr unknown
-
2015
- 2015-04-09 SM SM201500088T patent/SMT201500088B/xx unknown
-
2016
- 2016-05-06 US US15/148,792 patent/US20160250198A1/en not_active Abandoned
- 2016-12-22 US US15/388,902 patent/US20170100381A1/en not_active Abandoned
-
2017
- 2017-08-04 US US15/669,552 patent/US20170333411A1/en not_active Abandoned
-
2018
- 2018-03-12 US US15/918,685 patent/US20180200242A1/en not_active Abandoned
- 2018-10-31 US US16/176,902 patent/US20190060299A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20110478T1 (hr) | Modificiranje liječenja pirfenidonom za pacijente s atipičnom funkcijom jetre | |
JP2015517488A5 (de) | ||
JP2015518818A5 (de) | ||
MX2011008340A (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, dosificación farmacéutica de la misma, procesos para su preparación y usos de la misma para el control glucemico mejorado en un paciente. | |
UA105191C2 (ru) | Лечение пирфенидоном пациентов с атипической функцией печени | |
MX2017010763A (es) | Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo. | |
MX360554B (es) | Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2. | |
MX2018000084A (es) | Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina. | |
JP2013526535A5 (de) | ||
HRP20161796T1 (hr) | Farmaceutski pripravak za primjenu u tretmanu ili prevenciji deficijencije vitamina i minerala kod pacijenata podvrgnutih operaciji želučane premosnice | |
EA201390844A1 (ru) | Комплексный состав, содержащий гидрохлорид лерканидипина и валсартан, и способ его получения | |
NZ730267A (en) | Use of oxygen-enriched water composition | |
MX2015012666A (es) | Preparacion de complejo que incluye valsartan y rosuvastatina calcica y metodo de fabricacion para el mismo. | |
IN2013MU03428A (de) | ||
PH12017501918A1 (en) | Multi-peptide composition | |
MX2017013384A (es) | Composiciones que comprenden adamts13 para el uso en metodos para la recanalizacion de los vasos sanguineos ocluidos en un infarto. | |
MX2020011398A (es) | Metodos para tratar el sindrome de dolor regional complejo (crps) o sintomas que comprenden la administracion de acido neridronico. | |
Berthelot | Dabigatran etexilate | |
MX2016011002A (es) | Tratamiento de angioedema hereditario con inhibidor c1. | |
Song | Iodine 131 | |
MX2015002170A (es) | Nuevas composiciones farmaceuticas para el tratamiento de la hipertension. | |
Arthropathy | The Analgesic Efficacy of a COX-2 Inhibitor (Oral Celecoxib) in Adult | |
Eroglu | Anakinra/canakinumab/etanercept | |
You JiaFei et al. | Preoperative use of proton pump inhibitors in our hospital: analysis of 209 cases. | |
Beras | Liver injury: case report |